Ostial dimensional changes after pulmonary vein isolation: Pulsed field ablation vs radiofrequency ablation.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 03 2020
revised: 13 04 2020
accepted: 22 04 2020
pubmed: 8 5 2020
medline: 7 9 2021
entrez: 8 5 2020
Statut: ppublish

Résumé

Pulmonary vein (PV) stenosis is an important potential complication of PV isolation using thermal modalities such as radiofrequency ablation (RFA). Pulsed field ablation (PFA) is an alternative energy that causes nonthermal myocardial cell death. The purpose of this study was to compare the effect of PFA vs RFA on the incidence and severity of PV narrowing or stenosis. Data were analyzed from 4 paroxysmal atrial fibrillation ablation trials using either PFA or RFA; because of absent CT scans or poor computed tomography scan quality, 73 of 153 patients (47.7%) were excluded. Baseline and 3-month cardiac computed tomography scans were reconstructed into 3-dimensional images, and the long and short axes of the PV ostia were quantitatively and qualitatively assessed in a randomized blinded manner by 2 physicians. A total of 299 PVs from 80 patients after either PFA (n = 37) or RFA (n = 43) were enrolled. PV ostial diameters decreased significantly less with PFA than with RFA (% change; long axis: 0.9% ± 8.5% vs -11.9% ± 16.3%; P < .001 and short axis: 3.4% ± 12.7% vs -12.9% ± 18.5%; P < .001). After a combined quantitative/qualitative analysis, mild (30%-49%), moderate (50%-69%), or severe (70%-100%) PV narrowing was observed, respectively, in 9.0% (15 of 166), 1.8% (3 of 166), and 1.2% (2 of 166) of PVs in the RFA cohort but in none of the PVs after PFA (P < .001). Overall, PV narrowing/stenosis was present in 0% and 0% vs 12.0% and 32.5% of PVs and patients who underwent PFA and RFA, respectively. This study indicates that unlike after RFA, the incidence and severity of PV narrowing/stenosis after PV isolation is virtually eliminated with PFA.

Sections du résumé

BACKGROUND
Pulmonary vein (PV) stenosis is an important potential complication of PV isolation using thermal modalities such as radiofrequency ablation (RFA). Pulsed field ablation (PFA) is an alternative energy that causes nonthermal myocardial cell death.
OBJECTIVE
The purpose of this study was to compare the effect of PFA vs RFA on the incidence and severity of PV narrowing or stenosis.
METHODS
Data were analyzed from 4 paroxysmal atrial fibrillation ablation trials using either PFA or RFA; because of absent CT scans or poor computed tomography scan quality, 73 of 153 patients (47.7%) were excluded. Baseline and 3-month cardiac computed tomography scans were reconstructed into 3-dimensional images, and the long and short axes of the PV ostia were quantitatively and qualitatively assessed in a randomized blinded manner by 2 physicians.
RESULTS
A total of 299 PVs from 80 patients after either PFA (n = 37) or RFA (n = 43) were enrolled. PV ostial diameters decreased significantly less with PFA than with RFA (% change; long axis: 0.9% ± 8.5% vs -11.9% ± 16.3%; P < .001 and short axis: 3.4% ± 12.7% vs -12.9% ± 18.5%; P < .001). After a combined quantitative/qualitative analysis, mild (30%-49%), moderate (50%-69%), or severe (70%-100%) PV narrowing was observed, respectively, in 9.0% (15 of 166), 1.8% (3 of 166), and 1.2% (2 of 166) of PVs in the RFA cohort but in none of the PVs after PFA (P < .001). Overall, PV narrowing/stenosis was present in 0% and 0% vs 12.0% and 32.5% of PVs and patients who underwent PFA and RFA, respectively.
CONCLUSION
This study indicates that unlike after RFA, the incidence and severity of PV narrowing/stenosis after PV isolation is virtually eliminated with PFA.

Identifiants

pubmed: 32380290
pii: S1547-5271(20)30410-0
doi: 10.1016/j.hrthm.2020.04.040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1528-1535

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Kenji Kuroki (K)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

William Whang (W)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Charles Eggert (C)

Farapulse Inc, Menlo Park, California.

Jeff Lam (J)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Jonas Leavitt (J)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Iwanari Kawamura (I)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Ananya Reddy (A)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Blake Morrow (B)

Farapulse Inc, Menlo Park, California.

Christopher Schneider (C)

Farapulse Inc, Menlo Park, California.

Jan Petru (J)

Cardiology Department, Homolka Hospital, Prague, Czech Republic.

Mohit K Turagam (MK)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Jacob S Koruth (JS)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Marc A Miller (MA)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Subbarao Choudry (S)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Betsy Ellsworth (B)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Srinivas R Dukkipati (SR)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York.

Petr Neuzil (P)

Cardiology Department, Homolka Hospital, Prague, Czech Republic.

Vivek Y Reddy (VY)

Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York; Cardiology Department, Homolka Hospital, Prague, Czech Republic. Electronic address: vivek.reddy@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH